Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
LetterConsiderations in the Management of Gestational Diabetes Mellitus
Open Access

Issues With the Diagnosis and Classification of Hyperglycemia in Early Pregnancy

H. David McIntyre, David A. Sacks, Linda A. Barbour, Denice S. Feig, Patrick M. Catalano, Peter Damm, Aidan McElduff
DOI: 10.2337/dc15-1887 Published 1 January 2016
H. David McIntyre
1Mater Research, The University of Queensland, Brisbane, Queensland, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
  • For correspondence: david.mcintyre@mater.org.au
David A. Sacks
2Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Linda A. Barbour
3Divisions of Endocrinology, Metabolism and Diabetes and Maternal Fetal Medicine, University of Colorado, Denver, CO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Denice S. Feig
4Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Patrick M. Catalano
5Department of Reproductive Biology, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Peter Damm
6Center for Pregnant Women With Diabetes, Departments of Obstetrics and Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Aidan McElduff
7Discipline of Medicine, The University of Sydney, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site

In 2010, the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) panel published consensus-based recommendations on the diagnosis and classification of hyperglycemia in pregnancy (1). Within that document, the recommendations regarding early pregnancy testing were designed to facilitate early detection and treatment of hyperglycemia (HbA1c ≥6.5% [48 mmol/mol], fasting venous plasma glucose ≥7.0 mmol/L, random plasma glucose ≥11.1 mmol/L with confirmation) that, outside pregnancy, would be classified as diabetes. The term “overt diabetes” was suggested to describe these women. Subsequently, the World Health Organization (WHO) adopted the IADPSG criteria with some modifications and promoted the use of the term “diabetes in pregnancy” (2) for this group.

Cognizant that milder degrees of hyperglycemia would also be detected by early pregnancy testing, the IADPSG also recommended that fasting plasma glucose (FPG) in the range 5.1–6.9 mmol/L should be considered diagnostic of gestational diabetes mellitus (GDM) if noted at any time during pregnancy. More recent data from Italy (3) and China (4), where IADPSG diagnostic criteria were applied, have strongly challenged this recommendation, demonstrating a clear fall in FPG in early pregnancy and showing that early FPG ≥5.1 mmol/L is poorly predictive of later GDM at 24–28 weeks’ gestation. Zhu et al. (4) suggested using FPG 6.1–6.9 mmol/L “at the time of booking and the first prenatal visit” as a pragmatic criterion for GDM diagnosis in China. To date, similar data have not been reported in other populations.

We note that no randomized controlled trial data exist regarding the balance between additional benefits and costs of detecting and treating degrees of hyperglycemia less severe than “overt” diabetes from early pregnancy.

The potential utility of HbA1c in early pregnancy has also been addressed. In particular, a large cohort study from New Zealand (5) noted that HbA1c ≥5.9% (41 mmol/mol) identified all cases of WHO diabetes in pregnancy and was associated with a twofold risk of congenital anomalies, preeclampsia, and shoulder dystocia and a threefold risk of perinatal deaths. The use of HbA1c in this context is not currently endorsed by major national bodies and must carry some caveats because of the known limitations of the test. However, despite its poor sensitivity for impaired fasting glucose and impaired glucose tolerance, HbA1c may offer a pragmatic means of identifying women at high risk of serious pregnancy complications and warrants further detailed evaluation.

In conclusion, we suggest that the use of the IADPSG fasting glucose threshold of ≥5.1 mmol/L for the identification of GDM in early pregnancy is not justified by current evidence and that an early HbA1c ≥5.9% (41 mmol/mol) may identify women at higher risk for adverse pregnancy outcomes. In contrast to “standard” GDM testing at 24–32 weeks’ gestation, insufficient data exist to confidently recommend cutoff points for oral glucose tolerance testing in early pregnancy (e.g., prior to 20 weeks’ gestation). Current empirical approaches vary from application of “standard” (nonpregnant) thresholds to use of IADPSG/WHO thresholds throughout pregnancy. Normative data regarding early pregnancy glycemia and consequences of its detection and treatment are urgently required and should be a priority for future research.

Article Information

Duality of Interest. The authors are all members of the Council of the IADPSG and formed a writing group on behalf of the IADPSG. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. H.D.M. reviewed the literature and wrote the initial version of the manuscript. All authors contributed to discussions, critically reviewed and edited successive versions of the manuscript, and approved the final version. H.D.M. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Footnotes

  • See accompanying articles, pp. 13, 16, 24, 31, 39, 43, 50, 55, 61, and 65.

  • Received August 30, 2015.
  • Accepted September 6, 2015.
  • © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

    1. Metzger BE,
    2. Gabbe SG,
    3. Persson B, et al, .; International Association of Diabetes and Pregnancy Study Groups Consensus Panel
    . International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676–682
    1. Colagiuri S,
    2. Falavigna M,
    3. Agarwal MM, et al
    . Strategies for implementing the WHO diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Diabetes Res Clin Pract 2014;103:364–372
    1. Corrado F,
    2. D’Anna R,
    3. Cannata ML,
    4. Interdonato ML,
    5. Pintaudi B,
    6. Di Benedetto A
    . Correspondence between first-trimester fasting glycaemia and oral glucose tolerance test in gestational diabetes diagnosis. Diabetes Metab 2012;38:458–461
    1. Zhu WW,
    2. Yang HX,
    3. Wei YM, et al
    . Evaluation of the value of fasting plasma glucose in the first prenatal visit to diagnose gestational diabetes mellitus in China. Diabetes Care 2013;36:586–590
    1. Hughes RC,
    2. Moore MP,
    3. Gullam JE,
    4. Mohamed K,
    5. Rowan J
    . An early pregnancy HbA1c ≥5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes. Diabetes Care 2014;37:2953–2959

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.